Tharimmune, Inc. Announces Appointment of Vincent LoPriore to its Board of Directors
Bridgewater, NJ – April 15, 2025 – Tharimmune, Inc., a clinical-stage biotechnology company focused on advancing novel solutions in immunology and oncology, is pleased to announce the appointment of Vincent LoPriore to its Board of Directors. This appointment increases the size of the Board to seven members.
Background on Vincent LoPriore
Vincent LoPriore is the Founder of Gravitas Capital, a private investment firm, and Co-Founder of President Street Global, an investment management firm. He brings extensive experience in finance, business strategy, and operations to Tharimmune’s Board.
Impact on Tharimmune
With the addition of Mr. LoPriore to its Board of Directors, Tharimmune is poised to strengthen its strategic leadership and support the company’s next phase of growth and product development. His expertise in finance and business strategy will be invaluable as the company continues to advance its pipeline of innovative immunotherapies and oncology treatments.
Impact on Individuals
For individuals living with immune-related diseases or cancer, the appointment of Mr. LoPriore to Tharimmune’s Board of Directors could mean access to new and innovative treatments. Tharimmune’s focus on immunology and oncology means that the company is working on potential solutions for a range of conditions, including autoimmune diseases, infectious diseases, and various types of cancer. As the company progresses through clinical trials and regulatory approvals, these treatments could become available to patients.
Impact on the World
The biotechnology industry is making significant strides in the development of new treatments for a range of conditions, and Tharimmune’s appointment of Vincent LoPriore to its Board of Directors is a sign of the company’s commitment to innovation and growth. With his expertise in finance and business strategy, Mr. LoPriore will help guide Tharimmune as it navigates the complex regulatory landscape and brings its pipeline of treatments to market. The potential impact on individuals living with immune-related diseases or cancer is significant, as these treatments could offer new hope and improved outcomes.
Conclusion
Tharimmune, Inc.’s appointment of Vincent LoPriore to its Board of Directors is a significant step forward for the company as it continues to advance its pipeline of innovative immunotherapies and oncology treatments. Mr. LoPriore’s expertise in finance and business strategy will be invaluable as Tharimmune navigates the complex regulatory landscape and brings its treatments to market. For individuals living with immune-related diseases or cancer, this appointment could mean access to new and innovative treatments, offering hope for improved outcomes.
- Tharimmune appoints Vincent LoPriore to its Board of Directors
- LoPriore brings expertise in finance and business strategy
- Impact on Tharimmune: strengthened strategic leadership, support for growth and product development
- Impact on individuals: potential access to new and innovative treatments for immune-related diseases and cancer
- Impact on the world: commitment to innovation and growth in the biotechnology industry
